These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11939686)

  • 1. Rabbit syndrome secondary to risperidone.
    Hoy JS; Alexander B
    Pharmacotherapy; 2002 Apr; 22(4):513-5. PubMed ID: 11939686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.
    Nishimura K; Tsuka M; Horikawa N
    Eur Neuropsychopharmacol; 2001 Aug; 11(4):323-4. PubMed ID: 11532387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.
    Ren XS; Huang YH; Lee AF; Miller DR; Qian S; Kazis L
    J Clin Pharm Ther; 2005 Feb; 30(1):65-71. PubMed ID: 15659005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Eur J Clin Pharmacol; 2001 Jul; 57(4):327-31. PubMed ID: 11549212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.
    Miller DS; Yatham LN; Lam RW
    J Clin Psychiatry; 2001 Dec; 62(12):975-80. PubMed ID: 11780879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective prescribing of atypical antipsychotics.
    Breekveldt-Postma NS; Schillevoort I; Nolen WA; Veraart CP; Herings RM
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):25-30. PubMed ID: 15508132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone-induced rabbit syndrome: an unusual movement disorder.
    Sansare K; Singh D; Khanna V; Karjodkar FR
    N Y State Dent J; 2012; 78(5):44-6. PubMed ID: 23082694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic malignant syndrome with risperidone.
    Gleason PP; Conigliaro RL
    Pharmacotherapy; 1997; 17(3):617-21. PubMed ID: 9165568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.
    Yamada Y; Ohno Y; Nakashima Y; Fukuda M; Takayanagi R; Sato H; Tsuchiya F; Sawada Y; Iga T
    Synapse; 2002 Oct; 46(1):32-7. PubMed ID: 12211096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
    Knable MB; Heinz A; Raedler T; Weinberger DR
    Psychiatry Res; 1997 Sep; 75(2):91-101. PubMed ID: 9351491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
    Coley KC; Carter CS; DaPos SV; Maxwell R; Wilson JW; Branch RA
    J Clin Psychiatry; 1999 Dec; 60(12):850-6. PubMed ID: 10665632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
    Mulsant BH; Gharabawi GM; Bossie CA; Mao L; Martinez RA; Tune LE; Greenspan AJ; Bastean JN; Pollock BG
    J Clin Psychiatry; 2004 Dec; 65(12):1708-14. PubMed ID: 15641877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone-induced extrapyramidal reactions.
    Mahmood T; Clothier EB; Bridgman R
    Lancet; 1995 Nov; 346(8984):1226. PubMed ID: 7475677
    [No Abstract]   [Full Text] [Related]  

  • 19. Extrapyramidal symptoms in patients treated with risperidone.
    Simpson GM; Lindenmayer JP
    J Clin Psychopharmacol; 1997 Jun; 17(3):194-201. PubMed ID: 9169965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?
    Schoretsanitis G; Haen E; Hiemke C; Gründer G; Stegmann B; Schruers KR; Veselinovic T; Lammertz SE; Paulzen M
    Int Clin Psychopharmacol; 2016 Sep; 31(5):259-64. PubMed ID: 27167902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.